Wuhan, China

Qiang Xiao

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 14.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Hubei, CN (2017)
  • Wuhan, CN (2020)

Company Filing History:


Years Active: 2017-2020

where 'Filed Patents' based on already Granted Patents

3 patents (USPTO):

Title: Qiang Xiao: Innovator in Pharmaceutical Chemistry

Introduction

Qiang Xiao is a prominent inventor based in Wuhan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 3 patents to his name, his work focuses on innovative solutions for treating various diseases.

Latest Patents

Among his latest patents is a pyrimidine derivative that serves as an ALK inhibitor. This compound is designed for preparing an anti-tumor medicament aimed at suppressing anaplastic lymphoma kinase. Another notable patent involves a series of BTK inhibitors, which include compounds and their pharmaceutically acceptable salts, tautomer forms, or prodrugs. These inventions highlight his commitment to advancing therapeutic options in oncology.

Career Highlights

Qiang Xiao has worked with esteemed organizations such as the Hubei Bio-pharmaceutical Industrial Technological Institute and Humanwell Healthcare Group. His experience in these institutions has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical sector.

Collaborations

Throughout his career, Qiang has collaborated with notable colleagues, including Xuehai Wang and Yong Xu. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Qiang Xiao's contributions to pharmaceutical chemistry through his patents and collaborations underscore his role as a key innovator in the field. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…